MAPT and Cognitive impairment: CSF amyloid beta (Aβ)1–42, total tau (T-tau), and phosphorylated tau (P-tau) have utility in differentiating AD from controls and in predicting conversion from mild cognitive impairment (MCI) to AD dementia [1, 2].